BIOLOGICAL MIMETICS, INC.

Frederick, MD · Biotech · Private

gamma radiation-inactivated whole-cell MRSA vaccine produced using a novel antioxidant protection method derived from Deinococcus radiodurans

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Frederick, MD
Total capital: $14.7M

Federal grants: $10.1M; 21 awards · 2015–2026; Rank in peer group#51 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $4.6M; 6 awards · Interior, Defense, Health and Human S; Rank in Biotech#88 of 4373
Granted patents: 4; 14 pending · first 2018; Rank in peer group#85 of 514

Capital timeline

Latest events

May 2026Federal grantHealth and Human S · Phase I · A Subunit Vaccine Against Acinetobacter Baumannii$278K
Sep 2025Federal contractHealth and Human S · Phase II SBIR Biological Mimetics, Inc. Award$1.5M
Aug 2025Federal grantHealth and Human S · Phase I · An instrument-free malaria diagnostic$291K
Dec 2024Federal grantHealth and Human S · Phase I · A Subunit Vaccine Against Acinetobacter Baumannii$288K
Aug 2024Federal grantHealth and Human S · Phase I · Development of a Staph Aureus Vaccine$296K
May 2024Federal grantHealth and Human S · Phase I · An instrument-free malaria diagnostic$298K
May 2024Federal grantHealth and Human S · Phase II · Nonclinical Development of an Improved Polio Vaccine$917K

Show 20 earlier federal awards

Sep 2023Federal grantHealth and Human S · Phase I · Development of a Staph Aureus Vaccine$296K
Sep 2023Federal contractHealth and Human S · Phase I SBIR Biological Mimetics, Inc. Award$300K
Jul 2023Federal grantAgriculture · The U.S Pork Industry Produces An Estimated 2.2 Metric Tons Of Pork Annually, Valued At $23.4 Billion, Of Which 26% Is Exported To Other Countries (queck-matzie, 2019). Despite Significant Growth, Pork Production Continues To Be Hampered By Viruses, Such As PCV2, With Rapid Evolution And High Levels Of Genetic And Antigenic Variation. As New Strains Emerge, The Relevance Of Existing Vaccines Is Lost (constans, 2015; Meng, 2012). The Primary Goals Of This Proposal Are (1) To Develop An Improved P$175K
May 2023Federal grantHealth and Human S · Phase II · Nonclinical Development of an Improved Polio Vaccine$977K
Jun 2022Federal grantHealth and Human S · Phase II · Nonclinical Development of an Improved Polio Vaccine$991K
Jun 2021Federal grantHealth and Human S · Phase I · Development of a Universal Influenza Vaccine$299K
Jul 2020Federal grantHealth and Human S · Phase I · Development of a Universal Influenza Vaccine$299K
Apr 2019Federal grantHealth and Human S · Phase I · Whole-Cell Vaccine Development for MRSA$225K
Dec 2018Federal grantHealth and Human S · Phase I · Development of a cross-protective HRV vaccine$225K
Sep 2018Federal grantHealth and Human S · Phase I · Manganese-peptide Countermeasures for Radiation Exposure$299K
Jan 2018Federal grantHealth and Human S · Phase I · Improved RSV F Vaccine Candidates$225K
Jan 2018Federal grantHealth and Human S · Phase II · Development of an improved, low-cost polio vaccine (Ir-IPV)$723K
Jun 2017Federal contractDefense · Igf::ot::igf T2-0243 - STTR Phase II$1.1M
Feb 2017Federal grantHealth and Human S · Phase II · Development of an improved, low-cost polio vaccine (Ir-IPV)$743K
May 2016Federal grantHealth and Human S · Phase II · Development of the first HRV vaccine$1.0M
Sep 2015Federal contractDefense · Igf::ot::igf Ph I Proposal H151-051-0006$100K
Sep 2015Federal contractDefense · Igf::ot::igf Reports - STTR Phase I$150K
Jun 2015Federal grantHealth and Human S · Phase II · Development of the first HRV vaccine$1.0M
May 2015Federal grantHealth and Human S · Phase I · Development of a New Low-Cost Poliovirus Vaccine (Ir-IPV): Feasibility study with PV-2$225K
Sep 2008Federal contractInterior · New Contract Effort: Longitudinal Modeling For Spontaneous Emergence Of Modularity$1.4M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#51 · top 10%
Granted patents#85 · top 17%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 4 granted of 18

Sep 25, 2025PendingInactivated Staphylococcus Compositions And Methods Of Making And Using The SameUSPTOApplication 18863030
Mar 14, 2024PendingMulti-chamber Device For Detecting Pathogens/molecules And Methods Of Using SameUSPTOApplication 18464940
Oct 19, 2023PendingImmunogenic Human Rhinovirus (HRV) CompositionUSPTOApplication 17719779

Show all 18 patent records

Inactivated Staphylococcus Compositions And Methods Of Making And Using The SameSep 25, 2025 · Application 18863030Pending
Multi-chamber Device For Detecting Pathogens/molecules And Methods Of Using SameMar 14, 2024 · Application 18464940Pending
Immunogenic Human Rhinovirus (HRV) CompositionOct 19, 2023 · Application 17719779Pending
Immunogenic Influenza CompositionMar 1, 2022 · US 11,260,122Granted
Immunogenic Human Rhinovirus (HRV) CompositionMar 25, 2021 · Application 16827651Pending
Immunogenic Influenza CompositionSep 12, 2019 · Application 16420192Pending
Immunogenic Influenza CompositionMay 28, 2019 · US 10,300,125Granted
Immunogenic Influenza CompositionMay 14, 2019 · US 10,286,061Granted
Immunogenic Human Rhinovirus (HRV) CompositionMar 8, 2018 · Application 15811744Pending
Immunogenic Human Rhinovirus (hrv) CompositionsJan 23, 2018 · US 9,872,899Granted
Immunogenic Influenza CompositionApplication PCTUS2009034797Pending
Multi-chamber Devices For Detecting Pathogens/molecules And Methods Of Using SameApplication PCTUS2025019214Pending
Multi-chamber Device For Detecting Pathogens/molecules And Methods Of Using SameApplication PCTUS2023032485Pending
Inactivated Staphylococcus Compositions And Methods Of Making And Using The SameApplication PCTUS2023066663Pending
Measles Viruses With Reduced Susceptibility To NeutralizationApplication PCTUS2013051256Pending
Immunogenic Influenza CompositionApplication PCTUS2011022280Pending
Immunogenic Hiv CompositionApplication PCTUS2010047754Pending
Immunogenic Human Rhinovirus (hrv) CompositionsApplication PCTUS2014029891Pending

Biomedical Research Models, Inc.Similar federal contract value in Biotech · $4.6M in contracts
SORRENTO THERAPEUTICS, INC.Similar federal contract value in Biotech · $4.6M in contracts
FD NEUROTECHNOLOGIES CONSULTING & SERVICES, INC.Similar federal contract value in Biotech · $4.6M in contracts
Unchained LabsSimilar federal contract value in Biotech · $4.4M in contracts
NANOCELLECT BIOMEDICAL INCSimilar federal contract value in Biotech · $4.3M in contracts
BIOINFOEXPERTS LLCSimilar federal contract value in Biotech · $4.3M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.